Análisis de la aplicación intramuscular en pacientes que realizan tratamiento con Paliperidona de Liberación Prolongada Mensual o Trimestral: Diferencias de Género
Analysis of the intramuscular application of patients receiving Paliperidone Long Term Release Liberation Monthly or Quarterly: Gender Differences
Resumen
Abstract
Bibliografía
1. Ficha Técnica Trevicta. The European Medicines Agency (EMA) [Internet]. 2018 [citado 6 mayo 2018]. Disponible en: http://www.ema.europa.eu/docs/es_ES/ document_library/EPAR_-_Product_Information/human/004066/WC500180640.pdf
2. Ficha Técnica Xeplion. The European Medicines Agency (EMA) [Internet]. 2020 [citado 6 mayo 2018]. Disponible en: http://www.ema.europa.eu/docs/es_ ES/document library/EPAR_-Product_ Information/human/002105/ WC500103317.pdf
3.Cockshott WP, Thompson GT, Howlett LJ, Seeley ET. Intramuscular or intralipomatous injections? N Engl J Med. 1982 Aug 5;307(6):356-8.
4. Evans EF, Proctor JD, Fratkin MJ, Velandia J, Wasserman AJ. Blood flow in muscle groups and drug absorption. Clin Pharma-col Ther. 1975 Jan;17(1):44-7.
5. Haramati N1, Lorans R, Lutwin M, Kaleya RN. Injection granulomas. Intramuscle or intrafat? Arch Fam Med. 1994 Feb;3(2):146-8.
6. Cleton A, Rossenu S, Crauwels H, Berwaerts J, Hough D, Gopal S, Eerdekens M, Vandebosch A, Remmerie B, De Meulder M, Rosso CM. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injec-tions of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. J Clin Pharmacol. 2014 Sep;54(9):1048-57.
7.Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1022-31.
8. Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. Clin Schizophr Relat Psychoses. 2014 Jul;8(2):101-9, 109A.
9. Gopal S, Vermeulen A, Nandy P, Ravenstijn P, Nuamah I, Buron Vidal JA, Berwaerts J, Savitz A, Hough D, Samtani MN. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin. 2015 Nov;31(11):2043-54.
10. Pandina GJ, Lindenmayer, JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J. A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia. J Clin Psychopharmacol 2010;30: 235-244.
- Resumen visto - 1071 veces
- PDF descargado - 28 veces